davewho wrote: seems some here can't read very well.
Novel Blood-Based Early Cancer Detection: Diagnostics in Development (ajmc.com)
Galleri Test
The Galleri multicancer early detection (MCED) test identifies cfDNA circulating in the blood through next-generation sequencing, which recognizes DNA methylation.25 The test aims to identify distinct methylation patterns that are associated with specific cancers to detect a number of those cancers early and simultaneously provide information about the organ of origin.25 Four trials are evaluating this technology, including the Circulating Cell-free Genome Atlas (CCGA), STRIVE, SUMMIT, and PATHFINDER studies (Table 4).26-29 The CCGA study served in the initial development of the test by analyzing blood and tumor tissue samples from 15,254 individuals from 142 sites in North America, including patients with newly diagnosed cancer (56%, N = 8584) and blood samples from patients without a diagnosis of cancer (44%, N = 6670). More than 50 different cancer types were included in the samples analyzed. The trial includes 3 subsets to evaluate the different analytic methods of MCED, the test’s ability to correctly identify the tissue of origin, and a confirmatory validation. Subsets 1 and 2 of the study have been completed with the third, a validation study, ongoing.26 The preliminary trial results for the CCGA were presented at the 2019 American Society of Clinical Oncology (ASCO) meeting.25 The trial included a sub-study of 6689 participants, of which 2482 had previously untreated cancer, and included 4207 without cancer.25 The preliminary results showed that the MCED test could detect 12 types of cancer at early stages, including anorectal, colorectal, esophageal, gastric, head and neck, hormone receptor-positive breast, liver, lung, ovarian, and pancreatic cancers, in addition to multiple myeloma and lymphoid neoplasms. These 12 cancers are expected to account for over half of cancer deaths in the United States.6 The specificity was set at 99.3%, and tissue of origin was correctly identified with 93% accuracy. The test had a 67.3% (95% CI, 60.7%-73.3%) detection rate for the 12 prespecified cancer types across stages I to III, including 39% for stage I, 69% for stage II, and 83% for stage III. The overall detection rate for all cancer types was 43.9% (95% CI, 39.4%-48.5%) across stages I to III.
Galleri test trials
Pathfinder 2022
CCGA 2024
STRIVE 2025
SUMMIT 2030